Plant Advanced Technologies SA (ALPAT.PA)
EUR 11.7
(-2.5%)
EUR 11.7
(-2.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -778.23 Thousand EUR | 58.2% |
| 2022 | -1.86 Million EUR | 38.69% |
| 2021 | -3.03 Million EUR | -6.71% |
| 2020 | -2.84 Million EUR | -88.18% |
| 2019 | -1.51 Million EUR | -71411.99% |
| 2018 | -2114.88 EUR | -13.3% |
| 2017 | -1866.69 EUR | -1.34% |
| 2016 | -1841.98 EUR | -36.04% |
| 2015 | -1353.98 EUR | -25.12% |
| 2014 | -1082.18 EUR | 99.74% |
| 2013 | -409.23 Thousand EUR | -150.04% |
| 2012 | -163.66 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 FY | -778.23 Thousand EUR | 58.2% |
| 2023 Q2 | - EUR | 0.0% |
| 2022 Q4 | 227 Thousand EUR | 0.0% |
| 2022 FY | -1.86 Million EUR | 38.69% |
| 2022 Q2 | -2.08 Million EUR | 0.0% |
| 2021 Q4 | -1.31 Million EUR | 0.0% |
| 2021 FY | -3.03 Million EUR | -6.71% |
| 2021 Q2 | -1.87 Million EUR | 0.0% |
| 2020 Q4 | -512.04 Thousand EUR | 0.0% |
| 2020 FY | -2.84 Million EUR | -88.18% |
| 2020 Q2 | -1.08 Million EUR | 0.0% |
| 2019 FY | -1.51 Million EUR | -71411.99% |
| 2019 Q4 | -515.27 Thousand EUR | 0.0% |
| 2019 Q2 | -997.13 Thousand EUR | 0.0% |
| 2018 Q2 | -1061.89 EUR | 0.0% |
| 2018 Q4 | -1052.99 EUR | 0.0% |
| 2018 FY | -2114.88 EUR | -13.3% |
| 2017 Q4 | -648.79 EUR | 0.0% |
| 2017 FY | -1866.69 EUR | -1.34% |
| 2017 Q2 | -1217.90 EUR | 0.0% |
| 2016 Q2 | -1604.59 EUR | 0.0% |
| 2016 FY | -1841.98 EUR | -36.04% |
| 2016 Q4 | -237.39 EUR | 0.0% |
| 2015 FY | -1353.98 EUR | -25.12% |
| 2015 Q4 | -410.16 EUR | 0.0% |
| 2015 Q2 | -943.81 EUR | 0.0% |
| 2014 FY | -1082.18 EUR | 99.74% |
| 2014 Q2 | -818.43 EUR | 0.0% |
| 2014 Q4 | -263.76 EUR | 0.0% |
| 2013 Q1 | -121.13 Thousand EUR | 0.0% |
| 2013 Q3 | -121.13 Thousand EUR | -27684.46% |
| 2013 Q4 | 30.96 EUR | 100.03% |
| 2013 FY | -409.23 Thousand EUR | -150.04% |
| 2013 Q2 | -435.99 EUR | 99.64% |
| 2012 Q2 | -8263.00 EUR | 0.0% |
| 2012 Q3 | -8263.00 EUR | 0.0% |
| 2012 Q4 | -121.13 Thousand EUR | -1366.03% |
| 2012 FY | -163.66 Thousand EUR | 0.0% |
| 2012 Q1 | -8263.00 EUR | 0.0% |
| 2011 Q4 | -8263.00 EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | 77.191% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 99.389% |
| Adocia SA | -17.62 Million EUR | 95.584% |
| Aelis Farma SA | -6.46 Million EUR | 87.955% |
| Biophytis S.A. | -14.33 Million EUR | 94.57% |
| Advicenne S.A. | -6.45 Million EUR | 87.947% |
| genOway Société anonyme | 2.06 Million EUR | 137.682% |
| IntegraGen SA | -183.77 Thousand EUR | -323.484% |
| Medesis Pharma S.A. | -4.22 Million EUR | 81.599% |
| Neovacs S.A. | -6.9 Million EUR | 88.734% |
| NFL Biosciences SA | -4.43 Million EUR | 82.434% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | 75.194% |
| Sensorion SA | -22.31 Million EUR | 96.512% |
| Theranexus Société Anonyme | -7.64 Million EUR | 89.819% |
| TME Pharma N.V. | -5.62 Million EUR | 86.162% |
| Valbiotis SA | -7.16 Million EUR | 89.131% |
| TheraVet SA | -2.17 Million EUR | 64.221% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 96.164% |
| argenx SE | -417.15 Million EUR | 99.813% |
| BioSenic S.A. | -7.04 Million EUR | 88.945% |
| Celyad Oncology SA | -8.45 Million EUR | 90.798% |
| DBV Technologies S.A. | -85.24 Million EUR | 99.087% |
| Galapagos NV | -88.26 Million EUR | 99.118% |
| Genfit S.A. | -26.58 Million EUR | 97.072% |
| GeNeuro SA | -14.35 Million EUR | 94.58% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 95.134% |
| Innate Pharma S.A. | -12.66 Million EUR | 93.857% |
| Inventiva S.A. | -102.7 Million EUR | 99.242% |
| MaaT Pharma SA | -19.94 Million EUR | 96.098% |
| MedinCell S.A. | -20.97 Million EUR | 96.29% |
| Nanobiotix S.A. | -26.77 Million EUR | 97.094% |
| Onward Medical N.V. | -35.46 Million EUR | 97.805% |
| Oryzon Genomics S.A. | -4.54 Million EUR | 82.893% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 96.614% |
| Oxurion NV | -12.11 Million EUR | 93.574% |
| Pharming Group N.V. | -4.87 Million EUR | 84.051% |
| Poxel S.A. | -28.76 Million EUR | 97.294% |
| GenSight Biologics S.A. | -29.69 Million EUR | 97.379% |
| Transgene SA | -30.01 Million EUR | 97.407% |
| Financière de Tubize SA | -2.14 Million EUR | 63.701% |
| UCB SA | 604 Million EUR | 100.129% |
| Valneva SE | -82.08 Million EUR | 99.052% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 97.301% |